Elavil: Affected lots may exceed the interim acceptable intake limit for NNORT
Brand(s)
Last updated
Summary
Product
Elavil
Issue
Health products - Product safety
What to do
Consult your health care professional if you have any health concerns.
Distribution
Alberta
British Columbia
Newfoundland and Labrador
Ontario
Quebec
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
Elavil FCT 10 MG |
Elavil |
DIN 00335053 |
Tablet |
Amitriptyline Hydrochloride 10 mg |
TF8594, TF8597, RW8596 |
Elavil FCT 25 MG |
Elavil |
DIN 00335061 |
Tablet |
Amitriptyline Hydrochloride 25 mg |
TF8600 |
Issue
Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-nortriptyline (NNORT)
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Previous recalls or alerts
Background
Depth of recall: Wholesalers, Retailers, Healthcare Establishments
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
AA Pharma Inc.
1165 Creditstone Road Unit #1, Concord, ON L4K 4N7
Published by
Health Canada
Audience
General public
Healthcare
Industry
Distribution
Alberta
British Columbia
Newfoundland and Labrador
Ontario
Quebec
Recall class
Type I
Identification number
RA-76359
Get notified
Receive emails about new and updated recall and safety alerts.